OA13309A - Pyrimidine derivatives for the treatment of abnormal cell growth. - Google Patents

Pyrimidine derivatives for the treatment of abnormal cell growth. Download PDF

Info

Publication number: OA13309A
Authority: OA; OAPI
Prior art keywords: alkyl; cycloalkyl; ylamino; dihydro; indol
Prior art date: 2002-12-20

Application number

OA1200600067A

Other languages

English (en)

Inventor

John Charles Kath

Michael Joseph Luzzio

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-20

Filing date

2003-12-08

Publication date

2007-04-13

2003-12-08 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-04-13 Publication of OA13309A publication Critical patent/OA13309A/en

Links

230000010261 cell growth Effects 0.000 title claims abstract description 31
230000002159 abnormal effect Effects 0.000 title claims abstract description 27
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract description 3
150000003230 pyrimidines Chemical class 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 claims abstract description 232
241000124008 Mammalia Species 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
125000000217 alkyl group Chemical group 0.000 claims description 441
229910052739 hydrogen Inorganic materials 0.000 claims description 187
239000001257 hydrogen Substances 0.000 claims description 187
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 171
229910052736 halogen Inorganic materials 0.000 claims description 159
150000002367 halogens Chemical class 0.000 claims description 159
125000000753 cycloalkyl group Chemical group 0.000 claims description 156
125000004093 cyano group Chemical group *C#N 0.000 claims description 133
125000000623 heterocyclic group Chemical group 0.000 claims description 123
-1 (C^CeJheteroaryl Chemical group 0.000 claims description 113
229910052684 Cerium Inorganic materials 0.000 claims description 110
125000003118 aryl group Chemical group 0.000 claims description 79
125000001424 substituent group Chemical group 0.000 claims description 71
125000003342 alkenyl group Chemical group 0.000 claims description 67
125000001072 heteroaryl group Chemical group 0.000 claims description 67
125000000304 alkynyl group Chemical group 0.000 claims description 60
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 58
125000005842 heteroatom Chemical group 0.000 claims description 48
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 47
125000004429 atom Chemical group 0.000 claims description 44
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 39
229910052799 carbon Inorganic materials 0.000 claims description 37
125000004122 cyclic group Chemical group 0.000 claims description 33
150000001721 carbon Chemical group 0.000 claims description 28
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 27
125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims description 23
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 23
229910006074 SO2NH2 Inorganic materials 0.000 claims description 22
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
125000000565 sulfonamide group Chemical group 0.000 claims description 18
JYGFTBXVXVMTGB-UHFFFAOYSA-N Oxindol Natural products C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 17
229940002612 prodrug Drugs 0.000 claims description 17
239000000651 prodrug Substances 0.000 claims description 17
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 16
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 15
229910003844 NSO2 Inorganic materials 0.000 claims description 12
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
150000003254 radicals Chemical class 0.000 claims description 8
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 5
125000006692 (C2-C8) heterocyclyl group Chemical group 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
CDIUAGWPPOAFAC-UHFFFAOYSA-N 5-[[4-[(1-methylsulfonylpiperidin-3-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1N(S(=O)(=O)C)CCCC1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F CDIUAGWPPOAFAC-UHFFFAOYSA-N 0.000 claims description 2
FWAJFQHFUNMDCH-UHFFFAOYSA-N 5-[[4-[(1-methylsulfonylpyrrolidin-2-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound CS(=O)(=O)N1CCCC1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F FWAJFQHFUNMDCH-UHFFFAOYSA-N 0.000 claims description 2
SJMCNVUMRNUOKS-UHFFFAOYSA-N 5-[[4-[(3-methylsulfonylphenyl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound CS(=O)(=O)C1=CC=CC(CNC=2C(=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1 SJMCNVUMRNUOKS-UHFFFAOYSA-N 0.000 claims description 2
125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 2
NTVKGTDXILUFTF-UHFFFAOYSA-N 5-[[4-[(1-methylsulfonylpyrrolidin-3-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1N(S(=O)(=O)C)CCC1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F NTVKGTDXILUFTF-UHFFFAOYSA-N 0.000 claims 1
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 51
201000011510 cancer Diseases 0.000 abstract description 27
238000000034 method Methods 0.000 abstract description 26
150000002431 hydrogen Chemical class 0.000 description 111
102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 27
108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 27
239000000872 buffer Substances 0.000 description 24
239000003112 inhibitor Substances 0.000 description 24
210000004027 cell Anatomy 0.000 description 23
150000003839 salts Chemical class 0.000 description 21
239000002253 acid Substances 0.000 description 20
239000000243 solution Substances 0.000 description 20
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
238000004128 high performance liquid chromatography Methods 0.000 description 18
150000001412 amines Chemical class 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
239000000203 mixture Substances 0.000 description 15
229910019142 PO4 Inorganic materials 0.000 description 13
239000002585 base Substances 0.000 description 13
UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 12
108091000080 Phosphotransferase Proteins 0.000 description 12
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 12
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
102000020233 phosphotransferase Human genes 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
208000035475 disorder Diseases 0.000 description 11
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
239000012442 inert solvent Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
230000004913 activation Effects 0.000 description 9
125000003545 alkoxy group Chemical group 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
238000006366 phosphorylation reaction Methods 0.000 description 9
230000026731 phosphorylation Effects 0.000 description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
108091008598 receptor tyrosine kinases Proteins 0.000 description 8
239000011534 wash buffer Substances 0.000 description 8
102000001301 EGF receptor Human genes 0.000 description 7
108060006698 EGF receptor Proteins 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
208000002495 Uterine Neoplasms Diseases 0.000 description 7
230000001594 aberrant effect Effects 0.000 description 7
125000004104 aryloxy group Chemical group 0.000 description 7
238000003556 assay Methods 0.000 description 7
239000011575 calcium Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000012010 growth Effects 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
102000027426 receptor tyrosine kinases Human genes 0.000 description 7
238000012546 transfer Methods 0.000 description 7
206010046766 uterine cancer Diseases 0.000 description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
201000009030 Carcinoma Diseases 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
239000007995 HEPES buffer Substances 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
125000001153 fluoro group Chemical group F* 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
JPUYXUBUJJDJNL-UHFFFAOYSA-N 5-amino-1,3-dihydroindol-2-one Chemical compound NC1=CC=C2NC(=O)CC2=C1 JPUYXUBUJJDJNL-UHFFFAOYSA-N 0.000 description 5
208000026310 Breast neoplasm Diseases 0.000 description 5
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
125000001309 chloro group Chemical group Cl* 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
241000283707 Capra Species 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
206010061902 Pancreatic neoplasm Diseases 0.000 description 4
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
208000015634 Rectal Neoplasms Diseases 0.000 description 4
208000005718 Stomach Neoplasms Diseases 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
208000024770 Thyroid neoplasm Diseases 0.000 description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 4
230000000340 anti-metabolite Effects 0.000 description 4
229940100197 antimetabolite Drugs 0.000 description 4
239000002256 antimetabolite Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
201000010099 disease Diseases 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
206010017758 gastric cancer Diseases 0.000 description 4
208000014829 head and neck neoplasm Diseases 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 4
229960003248 mifepristone Drugs 0.000 description 4
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
201000002528 pancreatic cancer Diseases 0.000 description 4
208000008443 pancreatic carcinoma Diseases 0.000 description 4
102000013415 peroxidase activity proteins Human genes 0.000 description 4
108040007629 peroxidase activity proteins Proteins 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
206010038038 rectal cancer Diseases 0.000 description 4
201000001275 rectum cancer Diseases 0.000 description 4
238000011160 research Methods 0.000 description 4
150000003335 secondary amines Chemical class 0.000 description 4
201000011549 stomach cancer Diseases 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
210000001685 thyroid gland Anatomy 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
JQCGHRDKVZPCRO-UHFFFAOYSA-N 5-nitro-1,3-dihydroindol-2-one Chemical compound [O-][N+](=O)C1=CC=C2NC(=O)CC2=C1 JQCGHRDKVZPCRO-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010000830 Acute leukaemia Diseases 0.000 description 3
229920000936 Agarose Polymers 0.000 description 3
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
206010005949 Bone cancer Diseases 0.000 description 3
208000018084 Bone neoplasm Diseases 0.000 description 3
208000017897 Carcinoma of esophagus Diseases 0.000 description 3
229940123587 Cell cycle inhibitor Drugs 0.000 description 3
206010007953 Central nervous system lymphoma Diseases 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
208000000461 Esophageal Neoplasms Diseases 0.000 description 3
YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 3
208000017604 Hodgkin disease Diseases 0.000 description 3
208000010747 Hodgkins lymphoma Diseases 0.000 description 3
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
208000008839 Kidney Neoplasms Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
229910020700 Na3VO4 Inorganic materials 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
208000000821 Parathyroid Neoplasms Diseases 0.000 description 3
208000007913 Pituitary Neoplasms Diseases 0.000 description 3
201000005746 Pituitary adenoma Diseases 0.000 description 3
206010061538 Pituitary tumour benign Diseases 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
208000000453 Skin Neoplasms Diseases 0.000 description 3
208000021712 Soft tissue sarcoma Diseases 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
208000023915 Ureteral Neoplasms Diseases 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000003388 anti-hormonal effect Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
208000019065 cervical carcinoma Diseases 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
208000024207 chronic leukemia Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
210000001072 colon Anatomy 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
210000000750 endocrine system Anatomy 0.000 description 3
201000003914 endometrial carcinoma Diseases 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
201000001343 fallopian tube carcinoma Diseases 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
102000037979 non-receptor tyrosine kinases Human genes 0.000 description 3
108091008046 non-receptor tyrosine kinases Proteins 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
125000004043 oxo group Chemical group O=* 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
210000002990 parathyroid gland Anatomy 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
208000021310 pituitary gland adenoma Diseases 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
229940080818 propionamide Drugs 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
201000000849 skin cancer Diseases 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
210000000626 ureter Anatomy 0.000 description 3
210000003932 urinary bladder Anatomy 0.000 description 3
239000002525 vasculotropin inhibitor Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
GLOCCYSCJJXHNB-UHFFFAOYSA-N 5-[[4-(cyclopentylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NC1CCCC1 GLOCCYSCJJXHNB-UHFFFAOYSA-N 0.000 description 2
MLTLRJIDFKIARX-UHFFFAOYSA-N 5-[[4-[(5-methylsulfonylpyridin-3-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound CS(=O)(=O)C1=CN=CC(CNC=2C(=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1 MLTLRJIDFKIARX-UHFFFAOYSA-N 0.000 description 2
MNAGRIWYHIONAC-UHFFFAOYSA-N 5-[[4-[3-(methylamino)propylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NCCCNC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 MNAGRIWYHIONAC-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010006143 Brain stem glioma Diseases 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
241001227713 Chiron Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000009024 Epidermal Growth Factor Human genes 0.000 description 2
102400001368 Epidermal growth factor Human genes 0.000 description 2
101800003838 Epidermal growth factor Proteins 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
208000037147 Hypercalcaemia Diseases 0.000 description 2
206010061252 Intraocular melanoma Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
239000002841 Lewis acid Substances 0.000 description 2
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
102000004357 Transferases Human genes 0.000 description 2
108090000992 Transferases Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
201000005969 Uveal melanoma Diseases 0.000 description 2
201000003761 Vaginal carcinoma Diseases 0.000 description 2
108010084455 Zeocin Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000024447 adrenal gland neoplasm Diseases 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001345 alkine derivatives Chemical class 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
239000004037 angiogenesis inhibitor Substances 0.000 description 2
WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
230000002280 anti-androgenic effect Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000000051 antiandrogen Substances 0.000 description 2
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
230000035578 autophosphorylation Effects 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
229940077388 benzenesulfonate Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
150000004657 carbamic acid derivatives Chemical class 0.000 description 2
235000013877 carbamide Nutrition 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
208000030381 cutaneous melanoma Diseases 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940121647 egfr inhibitor Drugs 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
229940116977 epidermal growth factor Drugs 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
238000001914 filtration Methods 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
230000000148 hypercalcaemia Effects 0.000 description 2
208000030915 hypercalcemia disease Diseases 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000012444 intercalating antibiotic Substances 0.000 description 2
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
229940047889 isobutyramide Drugs 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
238000000021 kinase assay Methods 0.000 description 2
239000010410 layer Substances 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
150000007517 lewis acids Chemical class 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
208000026037 malignant tumor of neck Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
YSYRSSGVAPEIGG-UHFFFAOYSA-N n-methyl-n-[2-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]ethyl]methanesulfonamide Chemical compound C1=C(C(F)(F)F)C(NCCN(C)S(C)(=O)=O)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 YSYRSSGVAPEIGG-UHFFFAOYSA-N 0.000 description 2
150000002825 nitriles Chemical class 0.000 description 2
201000002575 ocular melanoma Diseases 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
210000004197 pelvis Anatomy 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 2
230000004044 response Effects 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
201000003708 skin melanoma Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
150000003457 sulfones Chemical class 0.000 description 2
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
235000011149 sulphuric acid Nutrition 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
230000002381 testicular Effects 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
210000003708 urethra Anatomy 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
208000013013 vulvar carcinoma Diseases 0.000 description 2
239000011701 zinc Substances 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
KMPLYESDOZJASB-PAHRJMAXSA-N (6s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-hydroxy-6-methoxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(z)-n-carbamoyl-2-ethylbut-2-enamide;6-ethoxy-1,3-benzothiazole-2-sulfonamide Chemical compound CC\C(=C\C)C(=O)NC(N)=O.CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](OC)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 KMPLYESDOZJASB-PAHRJMAXSA-N 0.000 description 1
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
MHNAXLAGKSOPBH-UHFFFAOYSA-N 1-amino-3h-indol-2-one Chemical compound C1=CC=C2N(N)C(=O)CC2=C1 MHNAXLAGKSOPBH-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
QMVPQBFHUJZJCS-NTKFZFFISA-N 1v8x590xdp Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 1
IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 1
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
MOZOZFCATOJNST-UHFFFAOYSA-N 2-methoxy-n-methyl-n-[3-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]acetamide Chemical compound C1=C(C(F)(F)F)C(NCCCN(C)C(=O)COC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 MOZOZFCATOJNST-UHFFFAOYSA-N 0.000 description 1
125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 description 1
JJSAEDOMTCNEQL-UHFFFAOYSA-N 3-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-3-carboxamide Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCCOC1 JJSAEDOMTCNEQL-UHFFFAOYSA-N 0.000 description 1
NMDUJEUWNLCXSB-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl]amino]propanoic acid Chemical compound C1=CC(S(=O)(=O)N(CCC(O)=O)C(C)(C)C(=O)NO)=CC=C1OC1=CC=C(F)C=C1 NMDUJEUWNLCXSB-UHFFFAOYSA-N 0.000 description 1
WARXYAHFCARUNH-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonyl-[4-(hydroxycarbamoyl)oxan-4-yl]amino]propanoic acid Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCOCC1 WARXYAHFCARUNH-UHFFFAOYSA-N 0.000 description 1
YZIGEYGKVJNXSU-UHFFFAOYSA-N 3-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxolane-3-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOC1 YZIGEYGKVJNXSU-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
CYZMUIMLRBJSRO-UHFFFAOYSA-N 4-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 CYZMUIMLRBJSRO-UHFFFAOYSA-N 0.000 description 1
ZBRHTUMWSDPCMI-UHFFFAOYSA-N 4-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 ZBRHTUMWSDPCMI-UHFFFAOYSA-N 0.000 description 1
DBPKMSBWOKAKLA-UHFFFAOYSA-N 4-chloropyrimidine Chemical compound ClC1=CC=NC=N1 DBPKMSBWOKAKLA-UHFFFAOYSA-N 0.000 description 1
SBTITDHNZFVGGP-UHFFFAOYSA-N 5-[[4-(1,2,3,4-tetrahydronaphthalen-1-ylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1CCC2=CC=CC=C2C1NC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F SBTITDHNZFVGGP-UHFFFAOYSA-N 0.000 description 1
MXNGKJYHTMSXSM-UHFFFAOYSA-N 5-[[4-(1,3-dihydroxypropan-2-ylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(CO)CO)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 MXNGKJYHTMSXSM-UHFFFAOYSA-N 0.000 description 1
QKRHACSTGVLZMZ-UHFFFAOYSA-N 5-[[4-(1-hydroxybutan-2-ylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(CO)CC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 QKRHACSTGVLZMZ-UHFFFAOYSA-N 0.000 description 1
DJTHSSKGCKGYAB-UHFFFAOYSA-N 5-[[4-(1-hydroxypropan-2-ylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(CO)C)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 DJTHSSKGCKGYAB-UHFFFAOYSA-N 0.000 description 1
NATHUACHVPDMFH-UHFFFAOYSA-N 5-[[4-(1-methoxypropan-2-ylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(C)COC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 NATHUACHVPDMFH-UHFFFAOYSA-N 0.000 description 1
XFPPMICQXCBWLY-UHFFFAOYSA-N 5-[[4-(1h-imidazol-2-ylmethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCC1=NC=CN1 XFPPMICQXCBWLY-UHFFFAOYSA-N 0.000 description 1
XCTIKUHWAXALMA-UHFFFAOYSA-N 5-[[4-(2-methylbutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NCC(C)CC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 XCTIKUHWAXALMA-UHFFFAOYSA-N 0.000 description 1
DNTXYHNJUWUFCI-UHFFFAOYSA-N 5-[[4-(2-piperidin-2-ylethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCCC1CCCCN1 DNTXYHNJUWUFCI-UHFFFAOYSA-N 0.000 description 1
ABCACJCCEROXTM-UHFFFAOYSA-N 5-[[4-(3-methylsulfanylpropylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NCCCSC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 ABCACJCCEROXTM-UHFFFAOYSA-N 0.000 description 1
KDIMLCMOIGUMNM-UHFFFAOYSA-N 5-[[4-(5-bicyclo[2.2.1]hept-2-enylmethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C2NC(=O)CC2=CC(NC2=NC=C(C(=N2)NCC2C3CC(C=C3)C2)C(F)(F)F)=C1 KDIMLCMOIGUMNM-UHFFFAOYSA-N 0.000 description 1
JTHITTDCZMTHNC-UHFFFAOYSA-N 5-[[4-(cyclobutylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NC1CCC1 JTHITTDCZMTHNC-UHFFFAOYSA-N 0.000 description 1
LPXJSPMQDSMJKA-UHFFFAOYSA-N 5-[[4-(propylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NCCC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 LPXJSPMQDSMJKA-UHFFFAOYSA-N 0.000 description 1
ULHPJQXXNLJHFH-UHFFFAOYSA-N 5-[[4-(pyridin-4-ylmethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCC1=CC=NC=C1 ULHPJQXXNLJHFH-UHFFFAOYSA-N 0.000 description 1
FHHIWMYRUBLGQW-UHFFFAOYSA-N 5-[[4-(pyrimidin-2-ylmethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCC1=NC=CC=N1 FHHIWMYRUBLGQW-UHFFFAOYSA-N 0.000 description 1
ZBILRCLMDAKJGK-UHFFFAOYSA-N 5-[[4-[(1-hydroxy-3,3-dimethylbutan-2-yl)amino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(CO)C(C)(C)C)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 ZBILRCLMDAKJGK-UHFFFAOYSA-N 0.000 description 1
RTLZGYBIWXYKLD-UHFFFAOYSA-N 5-[[4-[(1-hydroxycyclopentyl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound N=1C(NC=2C=C3CC(=O)NC3=CC=2)=NC=C(C(F)(F)F)C=1NCC1(O)CCCC1 RTLZGYBIWXYKLD-UHFFFAOYSA-N 0.000 description 1
BELWMKBKMSVPKB-UHFFFAOYSA-N 5-[[4-[(1-pyrimidin-2-ylpiperidin-3-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCC(C1)CCCN1C1=NC=CC=N1 BELWMKBKMSVPKB-UHFFFAOYSA-N 0.000 description 1
RYHQAXUFLGVUCB-UHFFFAOYSA-N 5-[[4-[(3,3-dimethyl-2-oxobutyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NCC(=O)C(C)(C)C)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 RYHQAXUFLGVUCB-UHFFFAOYSA-N 0.000 description 1
NWRIXMGAZZRGMD-UHFFFAOYSA-N 5-[[4-[(3-cyclopropyl-1h-pyrazol-5-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCC(NN=1)=CC=1C1CC1 NWRIXMGAZZRGMD-UHFFFAOYSA-N 0.000 description 1
IFMBMJWTULILNE-UHFFFAOYSA-N 5-[[4-[(3-hydroxy-2,2-dimethylpropyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NCC(C)(CO)C)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 IFMBMJWTULILNE-UHFFFAOYSA-N 0.000 description 1
DNWBPYVSZZVPFN-UHFFFAOYSA-N 5-[[4-[(3-methylthiophen-2-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=CSC(CNC=2C(=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1C DNWBPYVSZZVPFN-UHFFFAOYSA-N 0.000 description 1
SYJOVGNUGRODDU-UHFFFAOYSA-N 5-[[4-[(4-methylsulfonylmorpholin-2-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1N(S(=O)(=O)C)CCOC1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F SYJOVGNUGRODDU-UHFFFAOYSA-N 0.000 description 1
FBVVJWFMGAAOOB-UHFFFAOYSA-N 5-[[4-[(5-methylfuran-2-yl)methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound O1C(C)=CC=C1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F FBVVJWFMGAAOOB-UHFFFAOYSA-N 0.000 description 1
BYDIZDIVXOXWKO-UHFFFAOYSA-N 5-[[4-[1-(2-methyl-1,3-thiazol-4-yl)ethylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound N=1C(NC=2C=C3CC(=O)NC3=CC=2)=NC=C(C(F)(F)F)C=1NC(C)C1=CSC(C)=N1 BYDIZDIVXOXWKO-UHFFFAOYSA-N 0.000 description 1
QXOMUEOQZXHBFG-UHFFFAOYSA-N 5-[[4-[2-(1-butanoylpiperidin-2-yl)ethylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound CCCC(=O)N1CCCCC1CCNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F QXOMUEOQZXHBFG-UHFFFAOYSA-N 0.000 description 1
ACAPBRNRZYKXBX-UHFFFAOYSA-N 5-[[4-[2-(2-hydroxyethylsulfanyl)ethylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound C1=C(C(F)(F)F)C(NCCSCCO)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 ACAPBRNRZYKXBX-UHFFFAOYSA-N 0.000 description 1
YHDNWJUMQHNFGT-UHFFFAOYSA-N 5-[[4-[2-(2-oxoimidazolidin-1-yl)ethylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCCN1CCNC1=O YHDNWJUMQHNFGT-UHFFFAOYSA-N 0.000 description 1
PXCAKIBHGGJZJW-SECBINFHSA-N 5-[[4-[[(2R)-butan-2-yl]amino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound [C@@H](C)(CC)NC1=NC(=NC=C1C(F)(F)F)NC=1C=C2CC(NC2=CC1)=O PXCAKIBHGGJZJW-SECBINFHSA-N 0.000 description 1
ICFFKADRTUYNSE-UHFFFAOYSA-N 5-[[4-[[3-(dimethoxyphosphorylmethyl)phenyl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound COP(=O)(OC)CC1=CC=CC(CNC=2C(=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1 ICFFKADRTUYNSE-UHFFFAOYSA-N 0.000 description 1
QGOMKAXFQSDXPX-UHFFFAOYSA-N 5-[[4-[[3-(methylsulfonylmethyl)phenyl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound CS(=O)(=O)CC1=CC=CC(CNC=2C(=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1 QGOMKAXFQSDXPX-UHFFFAOYSA-N 0.000 description 1
BLBZJJFMERFZCC-UHFFFAOYSA-N 5-[[4-[methyl(pyridin-2-ylmethyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound N=1C(NC=2C=C3CC(=O)NC3=CC=2)=NC=C(C(F)(F)F)C=1N(C)CC1=CC=CC=N1 BLBZJJFMERFZCC-UHFFFAOYSA-N 0.000 description 1
ISDVPGKWDWOFDA-UHFFFAOYSA-N 5-[[4-[methyl-[(1-methylsulfonylpiperidin-3-yl)methyl]amino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound N=1C(NC=2C=C3CC(=O)NC3=CC=2)=NC=C(C(F)(F)F)C=1N(C)CC1CCCN(S(C)(=O)=O)C1 ISDVPGKWDWOFDA-UHFFFAOYSA-N 0.000 description 1
CNFRSOCVKAXQJL-UHFFFAOYSA-N 5-[[4-[methyl-[(3-methylsulfonylphenyl)methyl]amino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound N=1C(NC=2C=C3CC(=O)NC3=CC=2)=NC=C(C(F)(F)F)C=1N(C)CC1=CC=CC(S(C)(=O)=O)=C1 CNFRSOCVKAXQJL-UHFFFAOYSA-N 0.000 description 1
HOGZZNGMPKWOTK-UHFFFAOYSA-N 5-[[5-(trifluoromethyl)-4-[[2-(trifluoromethyl)phenyl]methylamino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CC=CC=C1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F HOGZZNGMPKWOTK-UHFFFAOYSA-N 0.000 description 1
JCFWFUVJJOIEIM-UHFFFAOYSA-N 5-[[5-(trifluoromethyl)-4-[[3-(trifluoromethylsulfonyl)phenyl]methylamino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one Chemical compound FC(F)(F)C1=CN=C(NC=2C=C3CC(=O)NC3=CC=2)N=C1NCC1=CC=CC(S(=O)(=O)C(F)(F)F)=C1 JCFWFUVJJOIEIM-UHFFFAOYSA-N 0.000 description 1
231100000582 ATP assay Toxicity 0.000 description 1
241000220479 Acacia Species 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
108090000644 Angiozyme Proteins 0.000 description 1
125000006847 BOC protecting group Chemical group 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010065687 Bone loss Diseases 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
102100027995 Collagenase 3 Human genes 0.000 description 1
108050005238 Collagenase 3 Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
201000000054 Coronary Restenosis Diseases 0.000 description 1
206010056489 Coronary artery restenosis Diseases 0.000 description 1
VHHGUBHZBLPTKL-UHFFFAOYSA-N Cp-471358 Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(CCC(O)=O)C1(C(=O)NO)CCCC1 VHHGUBHZBLPTKL-UHFFFAOYSA-N 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
208000009849 Female Genital Neoplasms Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
102000018691 Focal Adhesion Kinase 1 Human genes 0.000 description 1
108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229940124761 MMP inhibitor Drugs 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
102100027998 Macrophage metalloelastase Human genes 0.000 description 1
101710187853 Macrophage metalloelastase Proteins 0.000 description 1
101150115111 Marchf7 gene Proteins 0.000 description 1
102100030417 Matrilysin Human genes 0.000 description 1
108090000855 Matrilysin Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100481410 Mus musculus Tek gene Proteins 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
238000007126 N-alkylation reaction Methods 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
102100030411 Neutrophil collagenase Human genes 0.000 description 1
101710118230 Neutrophil collagenase Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
241000150452 Orthohantavirus Species 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
101150093908 PDGFRB gene Proteins 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
208000007135 Retinal Neovascularization Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
102100030416 Stromelysin-1 Human genes 0.000 description 1
101710108790 Stromelysin-1 Proteins 0.000 description 1
102100028848 Stromelysin-2 Human genes 0.000 description 1
101710108792 Stromelysin-2 Proteins 0.000 description 1
102100028847 Stromelysin-3 Human genes 0.000 description 1
108050005271 Stromelysin-3 Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
108091008605 VEGF receptors Proteins 0.000 description 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
101500022167 Youcai mosaic virus Replicase small subunit Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
FDTOTQJHYIXABD-UHFFFAOYSA-N [3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]phenyl] methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=CC(CNC=2C(=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1 FDTOTQJHYIXABD-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000009471 action Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
150000003975 aryl alkyl amines Chemical class 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
150000003939 benzylamines Chemical class 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910000085 borane Inorganic materials 0.000 description 1
229940097269 borrelia burgdorferi Drugs 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229940088954 camptosar Drugs 0.000 description 1
OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
229950002826 canertinib Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
108010044165 crotoxin drug combination cardiotoxin Proteins 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
229960004132 diethyl ether Drugs 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
229950001287 edotecarin Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002081 enamines Chemical group 0.000 description 1
150000002085 enols Chemical class 0.000 description 1
SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229940050411 fumarate Drugs 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000000762 glandular Effects 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229940097042 glucuronate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000004475 heteroaralkyl group Chemical group 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
125000004282 imidazolidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])N([H])C1([H])* 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
150000002466 imines Chemical group 0.000 description 1
230000028993 immune response Effects 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
CNROXIRSPYGRRZ-UHFFFAOYSA-N n,2-dimethyl-n-[2-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]ethyl]butanamide Chemical compound C1=C(C(F)(F)F)C(NCCN(C)C(=O)C(C)CC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 CNROXIRSPYGRRZ-UHFFFAOYSA-N 0.000 description 1
BZNFWSNDJLASGN-UHFFFAOYSA-N n-[3-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]methanesulfonamide Chemical compound C1=C(C(F)(F)F)C(NCCCNS(=O)(=O)C)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 BZNFWSNDJLASGN-UHFFFAOYSA-N 0.000 description 1
PHOOOZKYKGXELN-UHFFFAOYSA-N n-[4-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]butyl]methanesulfonamide Chemical compound C1=C(C(F)(F)F)C(NCCCCNS(=O)(=O)C)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 PHOOOZKYKGXELN-UHFFFAOYSA-N 0.000 description 1
JFZSYBGSUSRCNW-UHFFFAOYSA-N n-[4-methyl-3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]phenyl]methanesulfonamide Chemical compound CC1=CC=C(NS(C)(=O)=O)C=C1CNC1=NC(NC=2C=C3CC(=O)NC3=CC=2)=NC=C1C(F)(F)F JFZSYBGSUSRCNW-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
XCDDGJSMHBPJAL-UHFFFAOYSA-N n-methyl-n-[3-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]acetamide Chemical compound C1=C(C(F)(F)F)C(NCCCN(C)C(C)=O)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 XCDDGJSMHBPJAL-UHFFFAOYSA-N 0.000 description 1
INEXTVFWFYAXPL-UHFFFAOYSA-N n-methyl-n-[3-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]ethanesulfonamide Chemical compound C1=C(C(F)(F)F)C(NCCCN(C)S(=O)(=O)CC)=NC(NC=2C=C3CC(=O)NC3=CC=2)=N1 INEXTVFWFYAXPL-UHFFFAOYSA-N 0.000 description 1
SEYCKJQCNUUPPN-UHFFFAOYSA-N n-methyl-n-[3-[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]morpholine-4-carboxamide Chemical compound N=1C(NC=2C=C3CC(=O)NC3=CC=2)=NC=C(C(F)(F)F)C=1NCCCN(C)C(=O)N1CCOCC1 SEYCKJQCNUUPPN-UHFFFAOYSA-N 0.000 description 1
FJDBOSSKQFIDKC-UHFFFAOYSA-N n-methyl-n-[4-methyl-3-[[[2-[(2-oxo-1,3-dihydroindol-5-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]methyl]phenyl]methanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=CC=C(C)C(CNC=2C(=CN=C(NC=3C=C4CC(=O)NC4=CC=3)N=2)C(F)(F)F)=C1 FJDBOSSKQFIDKC-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000003566 oxetanyl group Chemical group 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
101710135378 pH 6 antigen Proteins 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
229940093956 potassium carbonate Drugs 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003140 primary amides Chemical class 0.000 description 1
YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
108091006082 receptor inhibitors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000012453 solvate Substances 0.000 description 1
229910000080 stannane Inorganic materials 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000012089 stop solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003459 sulfonic acid esters Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000010998 test method Methods 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
208000013076 thyroid tumor Diseases 0.000 description 1
239000011135 tin Substances 0.000 description 1
229910052718 tin Inorganic materials 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
239000003558 transferase inhibitor Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
201000011294 ureter cancer Diseases 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000012130 whole-cell lysate Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200600067A 2002-12-20 2003-12-08 Pyrimidine derivatives for the treatment of abnormal cell growth. OA13309A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43567002P	2002-12-20	2002-12-20
US50074203P	2003-09-05	2003-09-05

Publications (1)

Publication Number	Publication Date
OA13309A true OA13309A (en)	2007-04-13

Family

ID=32685406

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200600067A OA13309A (en)	2002-12-20	2003-12-08	Pyrimidine derivatives for the treatment of abnormal cell growth.

Country Status (31)

Country	Link
US (4)	US7109335B2 (pl)
EP (1)	EP1625121B1 (pl)
AP (1)	AP2385A (pl)
AR (1)	AR043682A1 (pl)
AT (1)	ATE458731T1 (pl)
AU (2)	AU2003285614B2 (pl)
CA (1)	CA2529611C (pl)
CR (2)	CR8266A (pl)
CY (1)	CY1110069T1 (pl)
DE (1)	DE60331479D1 (pl)
DK (1)	DK1625121T3 (pl)
DO (1)	DOP2003000793A (pl)
EA (1)	EA013248B1 (pl)
EC (1)	ECSP066406A (pl)
ES (1)	ES2338545T3 (pl)
GE (1)	GEP20084357B (pl)
IL (1)	IL172047A (pl)
MX (1)	MXPA06002608A (pl)
MY (1)	MY142109A (pl)
NL (1)	NL1025067C2 (pl)
NZ (1)	NZ543719A (pl)
OA (1)	OA13309A (pl)
PA (1)	PA8593001A1 (pl)
PE (1)	PE20041016A1 (pl)
PL (1)	PL379330A1 (pl)
PT (1)	PT1625121E (pl)
RS (1)	RS20060097A (pl)
SI (1)	SI1625121T1 (pl)
TN (1)	TNSN06074A1 (pl)
TW (1)	TWI283673B (pl)
WO (1)	WO2004056807A1 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
CA2529611C (en)	2002-12-20	2009-12-15	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
DE10349423A1 (de) *	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20060205945A1 (en) *	2004-05-14	2006-09-14	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) *	2004-05-14	2005-11-24	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510963A (pt)	2004-05-14	2007-11-20	Pfizer Prod Inc	derivados pirimidina para o tratamento do crescimento anormal de células
MXPA06013164A (es)	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2005111023A1 (en) *	2004-05-14	2005-11-24	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
JP4812763B2 (ja) *	2004-05-18	2011-11-09	ライジェルファーマシューティカルズ，インコーポレイテッド	シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
BRPI0512342A (pt) *	2004-06-21	2008-03-04	Pharmacia & Upjohn Co Llc	métodos para aumento ósseo
EP1741709A1 (en)	2005-06-28	2007-01-10	Sanofi-Aventis Deutschland GmbH	Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
DK1945631T3 (da) *	2005-10-28	2012-10-22	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
US8722884B2 (en)	2005-12-01	2014-05-13	Verastem, Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
US8193197B2 (en) *	2006-10-19	2012-06-05	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
DE102007010801A1 (de)	2007-03-02	2008-09-04	Bayer Cropscience Ag	Diaminopyrimidine als Fungizide
JP2010522697A (ja) *	2007-03-16	2010-07-08	ユニバーシティオブフロリダリサーチファウンデーション	キナーゼタンパク質結合阻害剤
DK2146779T3 (en) *	2007-04-18	2016-11-28	Pfizer Prod Inc	Sulfonylamid derivatives to treat abnormal cell growth.
KR101294731B1 (ko) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
AU2008275918B2 (en)	2007-07-17	2014-01-30	Rigel Pharmaceuticals, Inc.	Cyclic amine substituted pyrimidinediamines as PKC inhibitors
CL2009000600A1 (es) *	2008-03-20	2010-05-07	Bayer Cropscience Ag	Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
EP2161259A1 (de)	2008-09-03	2010-03-10	Bayer CropScience AG	4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US8410126B2 (en) *	2009-05-29	2013-04-02	Boehringer Ingelheim International Gmbh	Pyrimidine inhibitors of PKTK2
TW201100441A (en)	2009-06-01	2011-01-01	Osi Pharm Inc	Amino pyrimidine anticancer compounds
US8933227B2 (en)	2009-08-14	2015-01-13	Boehringer Ingelheim International Gmbh	Selective synthesis of functionalized pyrimidines
EP2464633A1 (en)	2009-08-14	2012-06-20	Boehringer Ingelheim International GmbH	Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
EP2395001A1 (en)	2010-05-21	2011-12-14	Chemilia AB	Novel pyrimidine derivatives
CN103003264B (zh)	2010-05-21	2014-08-06	切米利亚股份公司	嘧啶衍生物
US10420665B2 (en)	2010-06-13	2019-09-24	W. L. Gore & Associates, Inc.	Intragastric device for treating obesity
US9526648B2 (en)	2010-06-13	2016-12-27	Synerz Medical, Inc.	Intragastric device for treating obesity
US8628554B2 (en)	2010-06-13	2014-01-14	Virender K. Sharma	Intragastric device for treating obesity
US10010439B2 (en)	2010-06-13	2018-07-03	Synerz Medical, Inc.	Intragastric device for treating obesity
DE102010034699A1 (de)	2010-08-18	2012-02-23	Merck Patent Gmbh	Pyrimidinderivate
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JP6000273B2 (ja)	2010-11-29	2016-09-28	オーエスアイ・ファーマシューティカルズ，エルエルシー	大環状キナーゼ阻害剤
EP2675794B1 (en)	2011-02-17	2019-02-13	Cancer Therapeutics Crc Pty Limited	Selective fak inhibitors
DK2675793T3 (en)	2011-02-17	2018-11-12	Cancer Therapeutics Crc Pty Ltd	FAK INHIBITORS
CA2830129C (en)	2011-03-24	2016-07-19	Chemilia Ab	Novel pyrimidine derivatives
EP2502924A1 (en)	2011-03-24	2012-09-26	Chemilia AB	Novel pyrimidine derivatives
DE102011111400A1 (de)	2011-08-23	2013-02-28	Merck Patent Gmbh	Bicyclische heteroaromatische Verbindungen
CA2850594C (en) *	2011-11-29	2020-03-10	F. Hoffmann-La Roche Ag	Aminopyrimidine derivatives as lrrk2 modulators
US20150005281A1 (en)	2011-12-23	2015-01-01	Cellzome Limited	Pyrimidine-2,4-diamine derivatives as kinase inhibitors
EP2711365A1 (en)	2012-09-21	2014-03-26	Chemilia AB	4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en)	2012-09-21	2014-03-26	Chemilia AB	4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US10779980B2 (en)	2016-04-27	2020-09-22	Synerz Medical, Inc.	Intragastric device for treating obesity
WO2019117813A1 (en) *	2017-12-15	2019-06-20	National University Of Singapore	Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
CN116888100B (zh) *	2021-04-08	2025-12-23	杭州阿诺生物医药科技有限公司	一种高活性的hpk1激酶抑制剂

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4507146A (en) *	1982-12-28	1985-03-26	Ciba-Geigy Corporation	2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
US4983608A (en) *	1989-09-05	1991-01-08	Hoechst-Roussell Pharmaceuticals, Inc.	N-substituted-4-pyrimidinamines and pyrimidinediamines
DE4029650A1 (de)	1990-09-19	1992-03-26	Hoechst Ag	2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
AU658646B2 (en)	1991-05-10	1995-04-27	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
DE4131184A1 (de)	1991-09-19	1993-03-25	Bayer Ag	Wasserbasierte, loesungsmittel- und emulgatorfreie mikrobizide wirkstoffkombination
WO1993010086A1 (de)	1991-11-13	1993-05-27	MTA Központi Kémiai Kutató Intézete	Verfahren zur herstellung von n-(arylsulfonyl)-carbamid-säure-derivaten und den in diesem verfahren verwendbaren intermedieren
DE4137291A1 (de)	1991-11-13	1993-05-19	Bayer Ag	Verfahren zur kontinuierlichen umsetzung von halogenpyrimidinen mit aminen
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
FR2686339B1 (fr)	1992-01-22	1994-03-11	Adir Cie	Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5521184A (en) *	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
ES2149815T3 (es)	1992-05-22	2000-11-16	Du Pont	Imidazolinonas fungicidas.
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en)	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9424233D0 (en)	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
IL123581A (en) *	1995-10-02	2001-09-13	Hoffmann La Roche	History of pyrimidine as receptor antagonists - 5HT2C, the process for their preparation and drugs containing them
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
TW440563B (en) *	1996-05-23	2001-06-16	Hoffmann La Roche	Aryl pyrimidine derivatives and a pharmaceutical composition thereof
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
ES2191187T3 (es)	1996-07-13	2003-09-01	Glaxo Group Ltd	Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
JP4386967B2 (ja)	1996-07-13	2009-12-16	グラクソ、グループ、リミテッド	プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
EA003188B1 (ru)	1996-08-06	2003-02-27	Пфайзер Инк	Замещенные пиридо- или пиримидосодержащие 6,6- или 6,7-бициклические производные
CA2264798A1 (en)	1996-09-04	1998-03-12	Pfizer Inc.	Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
DE19701931C1 (de)	1997-01-21	1998-05-28	Siemens Ag	Verfahren zur Detektion von Synchronizität zwischen mehreren digitalen Meßreihen mit Hilfe eines Rechners
PT968206E (pt)	1997-02-19	2007-02-28	Pharmacopeia Inc	Derivados n-heterocíclicos como inibidores de nos
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
NZ520093A (en)	1997-11-11	2004-03-26	Pfizer Prod Inc	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
BR9908004A (pt)	1998-02-17	2001-12-18	Tularik Inc	Composto, composição e método para prevençãoou supressão de uma infecção viral
DE69933680T2 (de)	1998-08-29	2007-08-23	Astrazeneca Ab	Pyrimidine verbindungen
US6297258B1 (en) *	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
BRPI9914164B8 (pt)	1998-09-29	2021-05-25	American Cyanamid Co	compostos de 3-ciano quinolina
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
GB9924862D0 (en) *	1999-10-20	1999-12-22	Celltech Therapeutics Ltd	Chemical compounds
MXPA02007957A (es) *	2000-02-17	2002-11-29	Amgen Inc	Inhibidores de cinasas.
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
NZ521117A (en)	2000-03-13	2005-02-25	Wyeth Corp	Method of treating or inhibiting colonic polyps
US6525051B2 (en)	2000-03-27	2003-02-25	Schering Aktiengesellschaft	N-heterocyclic derivatives as NOS inhibitors
AU2001269291A1 (en)	2000-07-07	2002-02-05	Cancer Research Technology Limited	Therapeutic acridone and acridine compounds
AU2001277621A1 (en)	2000-08-09	2002-03-04	Astrazeneca Ab	Antiangiogenic bicyclic derivatives
WO2002012227A2 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Indole, azaindole and indazole derivatives having vegf inhibiting activity
WO2002012228A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Cinnoline compounds
AU2001278609B2 (en)	2000-08-21	2005-04-14	Astrazeneca Ab	Quinazoline derivatives
JO2654B1 (en)	2000-09-04	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Multiple aryl caroxa amides are useful as lipid - lowering agents
ATE430742T1 (de)	2000-12-21	2009-05-15	Smithkline Beecham Corp	Pyrimidinamine als angiogenesemodulatoren
MEP13408A (en)	2001-05-29	2010-06-10	Bayer Schering Pharma Ag	Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en)	2001-05-30	2001-07-18	Astrazeneca Ab	Chemical compounds
HUP0402352A2 (hu) *	2001-06-19	2005-02-28	Bristol-Myers Squibb Co.	Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6939874B2 (en)	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
US6927293B2 (en)	2001-08-30	2005-08-09	Merck & Co., Inc.	Tyrosine kinase inhibitors
WO2003030909A1 (en)	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1438053B1 (de) *	2001-10-17	2008-09-10	Boehringer Ingelheim Pharma GmbH & Co.KG	Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
EP1453516A2 (de) *	2001-10-17	2004-09-08	Boehringer Ingelheim Pharma GmbH & Co.KG	5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
BR0307375A (pt)	2002-02-05	2004-12-07	Wyeth Corp	Processo para a sìntese de ácidos n-acil-2-amino-4-alcóxi-5-nitro-benzóicos
DE10205336A1 (de)	2002-02-07	2003-08-21	Bdd Group Holding Ag Zug	Deuterierte Biphenylderivate
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
AU2003231231A1 (en)	2002-05-06	2003-11-11	Bayer Pharmaceuticals Corporation	Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
BR0317467A (pt)	2002-12-20	2005-11-16	Arakis Ltd	Benzoxazocinas e seu uso como inibidores de reassimilação de monoaminas
CA2529611C (en) *	2002-12-20	2009-12-15	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) *	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005023780A1 (en) *	2003-09-05	2005-03-17	Pfizer Products Inc.	Selective synthesis of cf3-substituted pyrimidines
BRPI0510963A (pt) *	2004-05-14	2007-11-20	Pfizer Prod Inc	derivados pirimidina para o tratamento do crescimento anormal de células
MXPA06013164A (es) *	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
WO2005111024A1 (en) *	2004-05-14	2005-11-24	Pfizer Products Inc.	Pyrimidine derivatives for the treatment of abnormal cell growth

2003
- 2003-12-08 CA CA002529611A patent/CA2529611C/en not_active Expired - Lifetime
- 2003-12-08 DK DK03778613.4T patent/DK1625121T3/da active
- 2003-12-08 ES ES03778613T patent/ES2338545T3/es not_active Expired - Lifetime
- 2003-12-08 EP EP03778613A patent/EP1625121B1/en not_active Expired - Lifetime
- 2003-12-08 SI SI200331771T patent/SI1625121T1/sl unknown
- 2003-12-08 GE GEAP20039074A patent/GEP20084357B/en unknown
- 2003-12-08 MX MXPA06002608A patent/MXPA06002608A/es active IP Right Grant
- 2003-12-08 EA EA200600122A patent/EA013248B1/ru not_active IP Right Cessation
- 2003-12-08 RS YUP-2006/0097A patent/RS20060097A/sr unknown
- 2003-12-08 AU AU2003285614A patent/AU2003285614B2/en not_active Expired
- 2003-12-08 OA OA1200600067A patent/OA13309A/en unknown
- 2003-12-08 AP AP2005003438A patent/AP2385A/xx active
- 2003-12-08 WO PCT/IB2003/005883 patent/WO2004056807A1/en not_active Ceased
- 2003-12-08 DE DE60331479T patent/DE60331479D1/de not_active Expired - Lifetime
- 2003-12-08 AT AT03778613T patent/ATE458731T1/de active
- 2003-12-08 PT PT03778613T patent/PT1625121E/pt unknown
- 2003-12-08 PL PL379330A patent/PL379330A1/pl not_active Application Discontinuation
- 2003-12-11 US US10/733,215 patent/US7109335B2/en not_active Expired - Lifetime
- 2003-12-16 TW TW092135619A patent/TWI283673B/zh not_active IP Right Cessation
- 2003-12-17 DO DO2003000793A patent/DOP2003000793A/es unknown
- 2003-12-17 MY MYPI20034835A patent/MY142109A/en unknown
- 2003-12-18 NL NL1025067A patent/NL1025067C2/nl not_active IP Right Cessation
- 2003-12-18 PA PA20038593001A patent/PA8593001A1/es unknown
- 2003-12-18 AR ARP030104715A patent/AR043682A1/es unknown
2004
- 2004-01-05 PE PE2004000041A patent/PE20041016A1/es not_active Application Discontinuation
- 2004-12-08 NZ NZ543719A patent/NZ543719A/en not_active IP Right Cessation
2005
- 2005-11-20 IL IL172047A patent/IL172047A/en active IP Right Grant
2006
- 2006-03-02 CR CR8266A patent/CR8266A/es unknown
- 2006-03-03 EC EC2006006406A patent/ECSP066406A/es unknown
- 2006-03-03 TN TNP2006000074A patent/TNSN06074A1/en unknown
- 2006-08-17 US US11/506,689 patent/US7351712B2/en not_active Expired - Lifetime
2008
- 2008-03-31 US US12/059,889 patent/US7674796B2/en not_active Expired - Lifetime
- 2008-07-29 US US12/181,991 patent/US7741336B2/en not_active Expired - Lifetime
2009
- 2009-08-14 AU AU2009208172A patent/AU2009208172B2/en not_active Expired
2010
- 2010-04-20 CY CY20101100360T patent/CY1110069T1/el unknown
2011
- 2011-07-06 CR CR20110380A patent/CR20110380A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20060281774A1 (en)	2006-12-14
DE60331479D1 (de)	2010-04-08
US7674796B2 (en)	2010-03-09
IL172047A (en)	2012-04-30
AP2005003438A0 (en)	2005-12-31
CR8266A (es)	2007-01-18
AR043682A1 (es)	2005-08-10
PA8593001A1 (es)	2005-02-04
AU2003285614A1 (en)	2004-07-14
SI1625121T1 (sl)	2010-04-30
TW200426148A (en)	2004-12-01
WO2004056807A1 (en)	2004-07-08
US7741336B2 (en)	2010-06-22
MY142109A (en)	2010-09-15
EP1625121A1 (en)	2006-02-15
RS20060097A (sr)	2008-11-28
US20080300234A1 (en)	2008-12-04
EA200600122A1 (ru)	2006-06-30
DOP2003000793A (es)	2011-07-31
PE20041016A1 (es)	2004-12-30
ES2338545T3 (es)	2010-05-10
TWI283673B (en)	2007-07-11
IL172047A0 (en)	2009-02-11
EP1625121B1 (en)	2010-02-24
ATE458731T1 (de)	2010-03-15
ECSP066406A (es)	2006-09-18
US20050009853A1 (en)	2005-01-13
NZ543719A (en)	2007-01-26
PT1625121E (pt)	2010-03-11
AU2003285614B2 (en)	2009-05-14
MXPA06002608A (es)	2007-01-23
CY1110069T1 (el)	2015-01-14
US7351712B2 (en)	2008-04-01
NL1025067A1 (nl)	2004-06-22
NL1025067C2 (nl)	2005-02-15
AU2009208172A1 (en)	2009-09-10
CA2529611C (en)	2009-12-15
EA013248B1 (ru)	2010-04-30
TNSN06074A1 (en)	2007-10-03
CA2529611A1 (en)	2004-07-08
DK1625121T3 (da)	2010-05-10
US20080182840A1 (en)	2008-07-31
PL379330A1 (pl)	2006-08-21
AU2009208172B2 (en)	2011-06-16
CR20110380A (es)	2011-08-08
AP2385A (en)	2012-03-23
US7109335B2 (en)	2006-09-19
GEP20084357B (en)	2008-04-29

Publication	Publication Date	Title
OA13309A (en)	2007-04-13	Pyrimidine derivatives for the treatment of abnormal cell growth.
US7235562B2 (en)	2007-06-26	Pyrimidine derivatives for the treatment of abnormal cell growth
US8247411B2 (en)	2012-08-21	Sulfonyl amide derivatives for the treatment of abnormal cell growth
US7109337B2 (en)	2006-09-19	Pyrimidine derivatives for the treatment of abnormal cell growth
US20050256125A1 (en)	2005-11-17	Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566477A1 (en)	2005-11-24	Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566707A1 (en)	2005-11-24	Pyrimidine derivatives for the treatment of abnormal cell growth
US20060205945A1 (en)	2006-09-14	Pyrimidine derivatives for the treatment of abnormal cell growth
AU2016201820B2 (en)	2018-03-08	Sulfonyl amide derivatives for the treatment of abnormal cell growth
HK1158210A (en)	2012-07-13	Pyrimidine derivatives for the treatment of abnormal cell growth
HK1105203A (en)	2008-02-06	Pyrimidine derivatives for the treatment of abnormal cell growth
NO334841B1 (no)	2014-06-16	Pyrimidinderivater, fremgangsmåte for deres fremstilling, farmasøytisk preparater omfattende slike samt slike forbindelser for behandling av unormal cellevekst